Welcome: Guest | Site Use Options | Register | Login |

DARPA 2020 First-in-Human Therapeutic Interfering Particle (TIP) Targeting a Respiratory Virus

First-in-Human Therapeutic Interfering Particle (TIP) Targeting a Respiratory Virus

 Project Summary
Program: SBIR Agency: DARPA
Phase I Year: 2020 Phase II Year: 2020
Phase I Dollars: Phase II Dollars:
Principal Investigator:

   Phase I Abstract   
Respiratory viruses, such as Influenza A Virus (IAV), present aerosolizable biothreats with mass-casualty potential. Therapeutic Interfering Particles (TIPs) have been proposed as resistance-proof .....

   Phase II Abstract   
Respiratory viruses, such as Influenza A Virus (IAV), present aerosolizable biothreats with mass-casualty potential. Therapeutic Interfering Particles (TIPs) have been proposed as resistance-proof .....

Recipient Firm

101 6th Avenue
New York, NY 10013

(301) 502-7772
info@autonomous.bio
www.autonomous.bio

Principal point of contact
President/CEO:  N/A

SBIR firms in the news



Contact information

Innovation Development Institute, LLC

   45 Beach Bluff Avenue, Suite 300
     Swampscott,  MA 01907-1542

  Tel:  (781) 595-2920

  support@inknowvation.com